ReviewClinical medicine insights. Circulatory, respiratory and pulmonary medicine2015
Myriad Functions of Stanniocalcin-1 (STC1) Cover Multiple Therapeutic Targets in the Complicated Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF).
Review in Clinical medicine insights. Circulatory, respiratory and pulmonary medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- Immune mechanisms and novel therapies for idiopathic pulmonary fibrosis.Pharmaceutical science advances · 2024Review
- Cellular senescence and SASP in tumor progression and therapeutic opportunities.Molecular cancer · 2024Review
- From mechanism to therapy: the journey of CD24 in cancer.Frontiers in immunology · 2024Review
- Article
- ELTD1 Activation Induces an Endothelial-EMT Transition to a Myofibroblast Phenotype.International journal of molecular sciences · 2021Article
- Disrupting biological sensors of force promotes tissue regeneration in large organisms.Nature communications · 2021Article
- Therapeutic effects of placenta derived-, umbilical cord derived-, and adipose tissue derived-mesenchymal stem cells in chronicJournal of clinical biochemistry and nutrition · 2021Article
- TGF-β Induced CTGF Expression in Human Lung Epithelial Cells through ERK, ADAM17, RSK1, and C/EBPβ Pathways.International journal of molecular sciences · 2020Article
- Plasma proteomic biomarker signature of age predicts health and life span.eLife · 2020 · on this mapArticle
- A looming role of mitochondrial calcium in dictating the lung epithelial integrity and pathophysiology of lung diseases.Mitochondrion · 2020Review
- Expression, function and clinical application of stanniocalcin-1 in cancer.Journal of cellular and molecular medicine · 2020Review
- The power of proteomics to monitor senescence-associated secretory phenotypes and beyond: toward clinical applications.Expert review of proteomics · 2020Review
- A proteomic atlas of senescence-associated secretomes for aging biomarker development.PLoS biology · 2020Article
- Endothelial Stanniocalcin 1 Maintains Mitochondrial Bioenergetics and Prevents Oxidant-Induced Lung Injury via Toll-Like Receptor 4.Antioxidants & redox signaling · 2019Article
- Sevoflurane inhibits the progression of ovarian cancer through down-regulating stanniocalcin 1 (STC1).Cancer cell international · 2019Article
- Depletion of carbonic anhydrase IX abrogates hypoxia-induced overexpression of stanniocalcin-1 in triple negative breast cancer cells.Cancer biology & therapy · 2017Article
- Current Developments in Interstitial Lung Disease.Clinical medicine insights. Circulatory, respiratory and pulmonary medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic pulmonary fibrosis (IPF) is an intractable disease for which the pathological findings are characterized by temporal and spatial heterogeneity. The pathogenesis is composed of myriad factors, including repetitive injuries to epithelial cells, alterations in immunity, the formation of vascular leakage and coagulation, abnormal wound healing, fibrogenesis, and collagen accumulation. Therefore, the molecular target drugs that are used or attempted for treatment or clinical trials may not cover the myriad therapeutic targets of IPF. In addition, the complicated pathogenesis results in a lack of informative biomarkers to diagnose accurately the status of IPF. These facts point out the necessity of using a combination of drugs, that is, each single drug with molecular targets or a single drug with multiple therapeutic targets. In this review, we introduce a humoral factor, stanniocalcin-1 (STC1), which has myriad functions, including the maintenance of calcium homeostasis, the promotion of early wound healing, uncoupling respiration (aerobic glycolysis), reepithelialization in damaged tissues, the inhibition of vascular leakage, and the regulation of macrophage functions to keep epithelial and endothelial homeostasis, which may adequately cover the myriad therapeutic targets of IPF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.